Synthesis and antitumor activities of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives

• Full Papers • Previous Articles Next Articles

Synthesis and antitumor activities of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives

Xing Yan, Yu-Zhuo Ma, Jing-Bo Chen, Ying-Xiang Liu^*

1. School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China;
2. Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Kunming 650091, China;
3. School of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China

Received:2007-06-02 Revised:2007-11-10 Online:2007-12-15 Published:2007-12-15
Contact: Ying-Xiang Liu*

Abstract

Abstract: Aim To design and synthesize a series of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives, and to determine their antitumor activities in vitro. Method The target compounds were synthesized. Their antitumor activities were assayed using human hepatic carcinoma cell line (Bel-7402) and human oral cavity epidermis squamocellular carcinoma cell line (KB). Results Five compounds were obtained. Three of them were not reported in the literature and their chemical structures were confirmed by IR, 1H NMR, MS and elemental analysis. Preliminary screening results showed that compound 5 possessed better biological activity with IC50 1.62 μmol·L–1 against Bel-7402 and 8.04 μmol·L–1 against KB, but much weaker than 5-Fluorouracil. Conclusion Mannich base derivatives of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone exhibited some antitumor activities.

Key words: Chemical synthesis, Chemical synthesis, Benzylidenecyclopentanone substituted, Benzylidenecyclopentanone substituted, Antitumor activity, Antitumor activity

CLC Number:

R916.2

Supporting:

Xing Yan, Yu-Zhuo Ma, Jing-Bo Chen, Ying-Xiang Liu^*. Synthesis and antitumor activities of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives[J]. .

References

[1] Kupchan, S.M.; Eakin, M.A.; Thomus, A.M. J. Med. Chem. 1971, 14 (12): 1147–1152.
[2] Lee, K.H.; Meck, R.; Piantadosi, C.; Huang, E.S. J. Med. Chem. 1973, 16 (3): 299–301.
[3] Dimmock, J.R.; Kumar, P.; Nazarali, A.J.; Motaganahalli, N.L.; Kowalchuk, T.P.; Beazely, M.A.; Wilson Quail, J.; Oloo, E.O.; Allen, T.M.; Szydlowski, J.; DeClercq, E.; Balzarini, J. Eur. J. Med. Chem. 2000, 35(11): 967–977.
[4] Dimmock, J.R.; Raghavan, S.K.; Bigam, G.E. Eur. J. Med. Chem. 1988, 23 (2): 111–117.
[5] Dimmock, J.R.; Erciyas, E.; Bigam, G.E.; Kirkpatrick, D.L.; Duke, M.M. Eur. J. Med. Chem. 1989, 24 (4): 379–383.
[6] Zhou, S.L.; Ji, Z.Z. Chin. J. Med. Chem. 1990, 1(1): 26–33.
[7] Wang, J.L.; Zhao, L.X.; Wang, R.; Lu, M.; Chen, D.; Jing, Y.K. Bioorg. Med. Chem. 2005, 13(4): 1285–1291.
[8] Wang, W.; Liu, G.X.; Zheng, J. Eur. J. Pharmacol. 2007, 568(1): 61–67.
[9] Trachte, A.L.; Suthers, S.E.; Lerner, M.R.; Hanas, J.S.; Jupe, E.R.; Sienko, A.E.; Adesina, A.M.; Lightfoot, S.A.; Brackett, D.J.; Postier, R.G. Am. J. Surg. 2002, 184(6): 642–648.
[10] Adler, V.; Yin, Z.; Fuchs, S.Y.; Benezra, M.; Rosario, L.; Tew, K.D.; Pincus, M.R.; Sardana, M.; Henderson, C.J.; Wolf, C.R.; Davis, R.J.; Ronai, Z. EMBO J. 1999, 18(5): 1321–1334.
[11] Wang, T.; Arifoglu, P.; Ronai, Z.; Tew, K.D. J. Biol. Chem. 2001, 276(24): 20999–21003.
[12] Yin, Z.; Ivanov, V.N.; Habelhah, H.; Tew, K.D.; Ronai, Z. Cancer Res. 2000, 60(15): 4053–4057.
[13] Kamada, K.; Goto, S.; Okunaga, T.; Ihara, Y.; Tsuji, K.; Kawai, Y.; Uchida, K.; Osawa, T.; Matsuo, T.; Nagata, I.; Kondo, T. Free Radical Biol. Med. 2004, 37 (11): 1875–1884.
[14] Dimmock, J.R.; Smith, L.M. J. Pharm. Sci. 1980, 69 (5): 575–580.
[15] Ma, Y.Z.; Yin, L.N.; Liu, Y.X.; Mei, W.J.; Ji, Z.Z. Chin. J. Med. Chem. 2000, 16 (3): 144–149.